Clinical trials: Measles Vaccine
Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period…
- Conditions
- Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT02700230
- Testing
- Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Chikungunya Virus Infection
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection.
- Trial name
- NCT03807843
- Testing
- V184
- Where
- Puerto Rico
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Nasopharyngeal Carcinoma
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer.
- Trial name
- NCT04830267
- Testing
- Camrelizumab, Stereotactic body radiotherapy
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Chongqing University Cancer Hospital
Child Mortality, Child Morbidity
A Second Dose of Measles Vaccine (MV) in the Second Year of Life
This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life.
- Trial name
- NCT02943681
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 3,812 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+…
- Trial name
- HexAgon-HN (NCT06295731)
- Testing
- INBRX-106, Pembrolizumab
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 450 people
- Sponsor
- Inhibrx Biosciences, Inc
Covid19, Measles Vaccine
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?
Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them.
- Conditions
- Covid19, Measles Vaccine, Mortality
- Trial name
- NCT04468802
- Testing
- Case fatality rate
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Adenoid Cystic Carcinoma
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
- Trial name
- NCT07162480
- Testing
- P-Sam
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Iron Deficiencies
The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
- Trial name
- NCT06816524
- Testing
- Iron syrup, Multivitamin syrup, R21-Matrix/M Vaccine (malaria vaccine)
- Volunteers
- 324 people
- Sponsor
- Nicole Stoffel
Squamous Cell Carcinoma of the Head and Neck
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
The purpose of this study is to compare the pharmacokinetic, safety, immunogenicity and efficacy of CMAB819 and Nivolumab in subjects with recurrent or metastatic head and neck squamous cell carcinoma., after failure of prior…
- Trial name
- NCT04659369
- Testing
- CMAB819, Nivolumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Head and Neck Neoplasms, Carcinoma, Squamous Cell
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy.
- Trial name
- NCT01345682
- Testing
- Afatinib, Methotrexate
- Where
- 101 sites in United States, Argentina and 17 more
- Volunteers
- 483 people
- Sponsor
- Boehringer Ingelheim
Measles, Mumps
Making Decisions About the Measles-Mumps-Rubella Vaccine
The goal of this study is to determine whether a computer-based intervention that delivers individually-tailored educational messages about the MMR vaccine increases MMR vaccine-hesitant parents' intentions to have their children…
- Conditions
- Measles, Mumps, Rubella, MMR Vaccination
- Trial name
- NCT01369394
- Testing
- Behavioral: Computer-based tailoring system
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
The purpose of this study is to find out the effects, both good and bad, that a drug called ribavirin has on the patient and the cancer.
- Trial name
- NCT02308241
- Testing
- Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-target Heterologous Effects of Vaccines, Vaccine Interactions
The Interaction Between Measles and DTP Vaccination
The purpose of this study is to investigate for the broad immunological effects of administering measles vaccine (MV) and diphtheria-tetanus-whole cell pertussis vaccine (DTP) to 9 month old Gambian infants, either alone or…
- Trial name
- NCT02710045
- Testing
- Measles Vaccine at 9 months of age, DTP Vaccine at 9 months of age, Measles Vaccine at 18 months of age
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Medical Research Council Unit, The Gambia
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Measles
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).
- Trial name
- NCT00109278
- Testing
- V205C, measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head \& neck (1L…
- Trial name
- NCT05123950
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Bristol-Myers Squibb
Measles, Mumps
Immune Responses to Two Dose Varivax +/- MMR-II
This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00258726
- Testing
- MMR-II, Pro-Quad, Varivax
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)